Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database.
By R. Govindan, N. Page, D. Morgensztern, W. Read, R. Tierney, A. Vlahiotis, Edward L. Spitznagel, J. Piccirillo. Journal of Clinical Oncology, 2006
1,785 citations recorded by the source corpus.
Subfields: Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/9b74ec4ff40979ee2b342fea0cf59ff68b5cc33d
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. (2012, background): “initial response to chemotherapy but high relapse rates.(1) Study of SCLC biology is hindered by insuffi-”
- Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study (2020, background): “Small-cell lung cancer (SCLC) is an aggressive neuroendocrine malignancy strongly associated with tobacco use that accounts for approximately 15% of all lung cancers.(1) SCLC is characterized by a rapid doubling time and high growth fraction, and approximately two thirds of patients present with met”